BiotechTube

Emicizumab + rFVIIa + aPCC

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemophilia A

Conditions

Hemophilia A

Trial Timeline

Nov 18, 2015 → Dec 1, 2020

NCT ID
NCT02622321

About Emicizumab + rFVIIa + aPCC

Emicizumab + rFVIIa + aPCC is a phase 3 stage product being developed by Chugai Pharmaceutical for Hemophilia A. The current trial status is completed. This product is registered under clinical trial identifier NCT02622321. Target conditions include Hemophilia A.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02622321Phase 3Completed

Competing Products

20 competing products in Hemophilia A

See all competitors
ProductCompanyStageHype Score
EmicizumabChugai PharmaceuticalPhase 3
77
EmicizumabChugai PharmaceuticalPhase 3
77
Human Coagulation Factor VIIIChugai PharmaceuticalPhase 3
77
EmicizumabChugai PharmaceuticalPhase 3
77
Emicizumab + Factor VIII (FVIII)Chugai PharmaceuticalPhase 3
77
EmicizumabRochePhase 3
77
HEMLIBRAJohnson & JohnsonPre-clinical
23
EmicizumabRochePhase 3
77
EmicizumabRocheApproved
85
EmicizumabRochePhase 3
77
SPK-8011QQRochePhase 1/2
41
NXT007RochePhase 1/2
41
Emicizumab InjectionRochePhase 2
52
Bypassing Agents + FVIII ReplacementRochePre-clinical
23
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086PfizerPhase 2
51
Nonacog Alfa (Genetical Recombination)PfizerPre-clinical
22
Refacto AFPfizerPre-clinical
22
PF-06838435/ fidanacogene elaparvovecPfizerPhase 3
76
ReFacto AFPfizerPhase 3
76
Nonacog alfa + Nonacog alfaPfizerPhase 3
76

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77